Recurrent Glioblastoma Multiform(GBM) and resistant/recurrent malignant brain tumor. Malignant neoplasm of brain, unspecified
Conditions
Interventions
Intervention group: 5 patients with recurrent glioblastoma and resistant/recurrent malignant brain tumor are included in the study according to the inclusion criteria. The peripheral blood of one pare
Sponsors
Iranian academic center for education culture and research
Parsian Lotus Investment Bank
Eligibility
Sex/Gender
All
Age
3 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age: 3-65 Year Sex: Both Lansky/Karnofsky performance statue: 7-100% Life span expectation: >6 months Hemoglobin: > 10.0 g/dL AGC > 1,500/mm³ Platelet count > 100,000/mm³ Serum total bilirubin < 1.5 times upper limit of normal(ULN) ALT and AST < 2.5 times ULN Serum creatinine < 1.5 times ULN
Exclusion criteria
Exclusion criteria: Patients whose MRI or MRS view of the brain is in favor of radio necrosis Due to emergency conditions, the patient can not tolerate the new treatment Insufficient number of NK cells produced for treatment appearance new neurological ulcers after the first injection (after the wound heals, subsequent injections will be given if the patient is in good condition) diagnosis of any other invasive cancer within the past 5 years. Closing the reservare for the next injection (if this problem is solved, the injections will be done again. concurrent serious medical or psychiatric illness that may interfere with giving informed consent or conducting this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: After cell injection, every 2 hours up to 48 hours after cell injection. Method of measurement: Fever meter.;Hysteria. Timepoint: After cell injection, control the symptom up to 48 hours. Method of measurement: Patient checkup.;New neurological symptoms which not related to the tumor. Timepoint: Up to 48 hours after surgery, up to one week after cell injection. Method of measurement: Physical examination and recording of symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor size. Timepoint: One week after injection, every 2 weeks up to 3 months. Method of measurement: MRI and MRS.;Patient's survival. Timepoint: Every month up to 6 months. Method of measurement: Communicate with patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNiloufar Shayan Asl
Iranian academic center for education culture and research
Outcome results
None listed